Hidehito Horinouchi

Hidehito Horinouchi: COCOON trial on preventing dermatologic adverse events in EGFR-mutant NSCLC

Hidehito Horinouchi, Assistant Chief at National Cancer Center Hospital, shared a post on X:

“Now out.

COCOON: Preventing Moderate to Severe Dermatologic Adverse Events in First-line EGFR-mutant Advanced NSCLC Treated with Amivantamab Plus Lazertinib.

Presented by Nicolas Girard.

AEs ≥G2: OR 0.19 (95% CI, 0.09–0.40)

NCT06120140.”

Read further.

Hidehito Horinouchi: COCOON trial on preventing dermatologic adverse events in EGFR-mutant NSCLC

More posts featuring Hidehito Horinouchi.

cancer COCOON EGFR-mutant Advanced NSCLC ELCC25 Hidehito Horinouchi NSCLC OncoDaily Oncology